Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo-controlled clinical trial

International Archives of Allergy and Immunology

Volumn 162, Issue 1, 2013, Pages 89-93

  Iyengar, Shuba Rajashri ^a   Hoyte, Elizabeth G ^c   Loza, Angelica ^c   Bonaccorso, Salvatore ^c   Chiang, David ^c   Umetsu, Dale T ^b   Nadeau, Kari Christine ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; Cytokine expression; Immunoglobulin E; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 9; OMALIZUMAB; OX40 LIGAND; PLACEBO; THYMIC STROMAL LYMPHOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TH2 CELL; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL ARTICLE; CYTOMETRY; DRUG EFFECT; IMMUNOREACTIVITY; SCORING ATOPIC DERMATITIS; SKIN DISEASE ASSESSMENT;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; CYTOKINES; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN E; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879496768     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000350486     Document Type: Article

References (23)

1. Berger W, Gupta N, McAlary M, Fowler-Taylor A: Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 182-188.
2. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-1445.
3. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB: Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 1147-1154.
4. Kemp AS: Atopic eczema: Its social and financial costs. J Paediatr Child Health 1999; 35: 229-231.
5. Hirata T, Furie BC, Furie B: P-, e-, and l-selectin mediate migration of activated CD8+ T lymphocytes into inflamed skin. J Immunol 2002; 169: 4307-4313.
6. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal-Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ: Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-680.
7. Corrigan CJ, Jayaratnam A, Wang Y, Liu Y, de Waal Malefyt R, Meng Q, Kay AB, Phipps S, Lee TH, Ying S: Early production of thymic stromal lymphopoietin precedes infiltration of dendritic cells expressing its receptor in allergen-induced late-phase cutaneous responses in atopic subjects. Allergy 2009; 64: 1014-1022.
8. Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt ReW, Omori M, Zhou B, Ziegler SF: TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 2007; 25: 193-219.
9. Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Vasiadi M, Therianou A, Theoharides TC: IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One 2012; 7:e33271.
10. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, Andres C, Schnopp C, Ring J, Hein R, Ollert M, Mempel M: Lowdose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225.
11. Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohe C: Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: One year follow-up of omalizumab therapy. Eur J Med Res 2011; 16: 407-410.
12. Hamilton RG, Marcotte GV, Saini SS: Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005; 303: 81-91.
13. Severity scoring of atopic dermatitis: The SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology 1993; 186: 23-31.
14. Ebner S, Nguyen VA, Forstner M, Wang YH, Wolfram D, Liu YJ, Romani N: Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007; 119: 982-990.
15. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, Torii H, Asahina A, Onai N, Matsushima K, Tamaki K: Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation- regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535-541.
16. Holgate S, Smith N, Massanari M, Jimenez P: Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64: 1728-1736.
17. Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS, Liu MC: Decreases in human dendritic cell-dependent T(h)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010; 125: 896-901.e896.
18. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, Dekruyff RH, Schneider LC, Nadeau KC, Umetsu DT: Changes in antigenspecific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol 2012; 5: 267-276.
19. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW: A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127: 654-660.
20. Liu YJ: Thymic stromal lymphopoietin: Master switch for allergic inflammation. J Exp Med 2006; 203: 269-273.
21. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, Comeau MR, Campbell DJ, Ziegler SF: Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005; 202: 541-549.
22. Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, Bullens SL, Seeber S, Fuentes ME, Labrijn AF, Graus YM, Miller A, Schelegle ES, Hyde DM, Wu LC, Hymowitz SG, Martin F: In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin-driven atopic inflammation. J Clin Invest 2007; 117: 3868-3878.
23. Barrios JL, Paradis L, Desroches A: Efficacy of omalizumab therapy in a case of severe atopic dermatitis. Allergy Asthma Clin Immunol 2011; 7(suppl 2):A33.